ExodusPoint Capital Management LP Purchases New Shares in Certara, Inc. (NASDAQ:CERT)

ExodusPoint Capital Management LP acquired a new position in Certara, Inc. (NASDAQ:CERT) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,083,786 shares of the company’s stock, valued at approximately $11,542,000. ExodusPoint Capital Management LP owned approximately 0.67% of Certara at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CERT. Venturi Wealth Management LLC increased its position in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the last quarter. Blue Trust Inc. grew its stake in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in Certara by 204.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock worth $58,000 after purchasing an additional 3,656 shares during the last quarter. KBC Group NV raised its position in shares of Certara by 64.1% in the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after purchasing an additional 3,125 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after buying an additional 6,868 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CERT. TD Cowen started coverage on shares of Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target for the company. William Blair reissued a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Barclays upped their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Finally, Stephens reissued an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Certara presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Stock Performance

Shares of CERT stock opened at $9.55 on Friday. The company has a market cap of $1.54 billion, a P/E ratio of -47.75, a PEG ratio of 9.29 and a beta of 1.64. The business has a 50 day moving average of $12.14 and a two-hundred day moving average of $11.41. Certara, Inc. has a 52 week low of $9.21 and a 52 week high of $19.18. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.